Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-04-04 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-1.34 |
-0.66 |
0.68 |
50.75% |
2023-08-14 |
2023-06 |
-4.33 |
-3.55 |
0.78 |
18.01% |
2023-05-15 |
2023-03 |
0 |
N/A |
N/A |
N/A |
2023-03-16 |
2022-12 |
-6 |
-4.2 |
1.8 |
30.00% |
Date |
Firm |
Action |
From |
To |
2023-10-17 |
TD Cowen |
Downgrade |
Outperform |
Market Perform |
2023-07-25 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
Date |
Name |
Relation |
Quantity |
Description |
2023-11-07 |
BODMER MARK |
Officer |
25.73K |
Sale |
2023-01-22 |
CARRIERE STEPHEN J |
Officer |
203.00 |
Sale |
2022-05-26 |
DARZI LORD ARA |
Director |
342.47K |
Purchase |
2022-06-29 |
EPSTEIN DAVID R |
Director |
93.93K |
Conversion of Exercise of derivative security |
2022-05-26 |
FLAGSHIP VENTURES |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-11-07 |
GILL BALKRISHAN |
Chief Executive Officer |
17.76K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Flagship Pioneering Inc. |
2.52M |
8.19M |
13.39% |
2023-06-29 |
Michigan (State Of) Teachers Retirement System |
203.54K |
661.49K |
1.08% |
2023-06-29 |
Credit Suisse Ag/ |
180.52K |
586.69K |
0.96% |
2023-06-29 |
Vanguard Group Inc |
155.90K |
506.66K |
0.83% |
2023-06-29 |
Harbourvest Partners, LLC |
153.18K |
497.82K |
0.81% |
2023-06-29 |
FMR, LLC |
126.43K |
410.88K |
0.67% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
104.55K |
339.78K |
0.56% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
66.19K |
437.49K |
0.35% |
2023-06-29 |
Vanguard Extended Market Index Fund |
48.60K |
157.95K |
0.26% |
2023-05-30 |
Fidelity Growth Company K6 Fund |
30.21K |
82.48K |
0.16% |
2023-08-30 |
Variable Insurance Products Fund-Growth Portfolio |
23.35K |
154.31K |
0.12% |
2023-07-30 |
Fidelity Capital Appreciation Fund |
18.97K |
198.62K |
0.10% |
Split |
Date |
1 : 20 |
2023-06-30 |